These results suggest that therapeutic vaccination of SIV-infected macaques undergoing ART with polyICLC/AT-2 SIV is effective in the post-therapy control of viral replication.
Only people with a negative reaction are permitted to undergo immunization.
In contrast, levels of HIV Gag-specific antibodies were elicited similarly in macaques following immunization with MVAΔudg-gag and MVA-gag.
However, our results indicate that deletion of udg had no demonstrable effect on the overall levels of MVA-specific antibodies that were generated in vivo, in either mice or rhesus macaques, following immunization with Δudg or udg+ vectors.
In the present study, we have analyzed the magnitude and breadth of Gag-specific T-lymphocyte and antibody responses elicited in Rhesus macaques after immunization with DNA encoding a human LAMP/gag (hLAMP/gag) chimera.
In rhesus macaques, immunization with Man9-V3 induced V3-glycan-targeted antibodies.
In preclinical studies with macaques, immunization with Tat-based vaccines (both native protein and plasmid DNA) was shown to be immunogenic and effective in controlling virus replication and blocking disease onset [ 27– 30].
By 4 weeks following primary immunization, macaques immunized with MVAΔudg-gag exhibited significantly greater frequencies of Gag-specific CD8 T cells, which produced IFNγ in response to Gag peptide stimulation, than did animals immunized with MVA-gag (MVAΔudg-gag: range = 0.04 0.39, median = 0.094; MVA-gag: range = 0.01 0.07, median = 0.033) (Figure 9A).
We previously showed that Mane-A*10 positive animals infected with SIV/mac251 that undergo immune escape at KP9 have viral loads that resemble those of Mane-A*10 negative macaques [9].
Six macaques underwent a single vacuum-assisted core biopsy of the mammary gland in accordance with guidelines set forth by the University of California, Davis Animal Care and Use Committee.
The specificity concern is exacerbated by the fact that the cells that bind E641 I-Ab and OVA323-339:I-Ab do not undE641 I-AbandexpansiOVA323-339 I-AbzatiOVA323-339 I-Ab
